Sir, the idiopathic inXammatory myopathies (IIMs) are characterised by muscle weakness, electromyography (EMG), histological and biochemical features of muscle inXammation. Their classiWcation into clinicoserological syndromes is evolving in light of the myositis-associated autoantibody panel [1] . Anti-cytoplasmic aminoacyl-tRNA synthetase (ARS) antibodies are detected in 25-30% patients with IIMs [2] . These enzymes catalyse the binding of amino acids to their cognate tRNA molecules. ARS are frequently associated with extra-muscular manifestations (anti-synthetase syndrome, ASS) that include interstitial lung disease (ILD), non-erosive arthritis, fever, Raynaud's phenomenon and mechanic's hands [2] . Jo-1 (histidyltRNA-synthetase) is the most common autoantigenic target (20% of patients with IIMs) [2] , whereas anti-PL12 antibodies (alanyl-tRNA synthetase) occur in less than 3% of cases [1] .
We report the case of a 58-year-old male with IIM associated with anti-PL12 antibodies, who presented with marked widespread muscle pain in the absence of overt muscle weakness. He presented with a three-week history of severe, generalised, predominantly proximal muscle pain. He also reported polyarthralgia, exertional dyspnoea, dry cough and weight loss, without Raynaud's or sicca symptoms. Examination revealed low-grade pyrexia and exquisitely tender muscles. Notably, there was no proximal muscle weakness or neurological deWcit. Bibasal Wne endinspiratory crepitations were present but mechanic's hands, joint swelling and skin changes were absent, and Shirmer's test was negative.
Investigations revealed anaemia (haemoglobin 8.8 g/ dL), thrombocytosis (platelets 666 £ 10 9 /l), marked acute phase response (CRP 121 mg/l, ESR 79 mm/h), polyclonal hypergammaglobulinaemia and raised ALT 276 U/l (0-40). Renal function and serum ACE levels were normal. Serology demonstrated high-titre anti-nuclear (1:1,280, Wne speckled) and weakly positive anti-Ro antibodies (4 U/ml (0-2). Serum Western blotting revealed anti-PL12 antibodies. No other autoantibodies were detected (Jo-1, Mi2, PM/ Scl, Ku, PL-7, La, dsDNA, Smith, RNP, CCP, Scl-70, aCL, 2-GP1, RhF and ANCA).
Creatinine kinase was elevated 936 U/l (0-200); EMG showed early recruitment of short duration polyphasic action potentials, consistent with myositis. Magnetic resonance imaging (MRI) thighs demonstrated high signal within the semitendinosis muscle. Muscle histology conWrmed a Xorid inXammatory myopathy ( Fig. 1) with disruption, oedema, lymphocytic inWltrate and considerable macrophage inWltrate in the perimysial connective tissuetypical features of ARS-associated IIM. Pulmonary function tests showed restrictive spirometry with reduced corrected gas transfer. High-resolution thoracic computed tomography showed changes consistent with non-speciWc interstitial pneumonia. Screen for malignancy and infection, bone scan and echocardiography were normal, with no evidence of pulmonary arterial hypertension.
Treatment with prednisolone 60 mg daily resulted in improvement of dyspnoea and normalisation of CRP and CK. SigniWcant muscle pain persisted, requiring morphine. It was steroid-responsive, but only to high doses, with recurrence on dose reduction. There were no features of opioid-seeking behaviour, Wbromyalgia or neuropathic elements to the pain. A course of pulsed cyclophosphamide was commenced, with improvement in muscle pain after the Wrst dose.
To our knowledge, severe muscular pain and tenderness in the absence of weakness are atypical of ASS and have not been previously reported. Anti-PL12 antibodies are rare; therefore, their associated clinical phenotype is not well described, unlike the Jo-1 syndrome. A recent review summarised clinical features in 89 patients with anti-PL12 antibodies [3] . A further 18 cases have since been reported [4, 5] (total 107 cases, summarised in Fig. 2 ), although muscular involvement was documented in only 49 patients. ILD is common and usually precedes muscle involvement and may occur in isolation. ANAs and anti-Ro antibodies are the most frequently found concomitant antibodies [3] . Previous reports suggest that muscle involvement is uncommon and mild (often subclinical) [3, 4, 6] . Further reports and prospective studies will help reWne the clinical phenotype of anti-PL12 antibody-positive ASS subtype. 
Key point
Myositis in the anti-synthetase syndrome with anti-PL 12 antibodies may be painful and more prominent than previously described.
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